A Global Active Surveillance for Community Acquired Pneumonia

Not Applicable

Completed

• Conditions: Community Acquired Pneumonia
• Interventions: Procedure: Blood draw; Procedure: Chest X-ray; Procedure: urine specimen; Procedure: Nasopharyngeal swab; Procedure: sputum

• Registration Number: NCT00929721
• Lead Sponsor: Pfizer

Brief Summary

This study is an observational surveillance study to identify adults 50 years and older who present to a study healthcare facility with signs and symptoms of Community-Acquired Pneumonia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-06-26
• Study First Submitted QC: 2009-06-26
• Study First Posted: 2009-06-29
• Study Start: 2009-12
• Primary Completion: 2012-01
• Study Completion: 2012-02
• Status Verified: 2012-04
• Last Update Submitted: 2012-04-12
• Last Update Posted: 2012-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5172

Inclusion Criteria

• Adult subjects 50 years of age or older
• Subject must reside in the surveillance area
• Subjects who present to a study healthcare facility where the treating physician clinically suspects CAP

Exclusion Criteria

• Any subject who is transferred to a study healthcare facility after already being hospitalized for 48 hours or more at any other in-patient facility (such as a community hospital).
• Hospital Acquired pneumonia (ie, develops signs and symptoms of pneumonia after being hospitalized for 48 hours or more).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Subjects with Community-Acquired Pneumonia	Blood draw	Subjects with Community-Acquired Pneumonia
Subjects with Community-Acquired Pneumonia	Chest X-ray	Subjects with Community-Acquired Pneumonia
Subjects with Community-Acquired Pneumonia	urine specimen	Subjects with Community-Acquired Pneumonia
Subjects with Community-Acquired Pneumonia	Nasopharyngeal swab	Subjects with Community-Acquired Pneumonia
Subjects with Community-Acquired Pneumonia	sputum	Subjects with Community-Acquired Pneumonia

Primary Outcome Measures

Name	Time	Method
Incidence rates of CAP in adults 50 years and older	up to 120 days from enrollment

Secondary Outcome Measures

Name	Time	Method
Frequency of bacterial agents associated with CAP, Case fatality and incidence rates of CAP number and characteristics of subjects from outpatient clinics, emergency rooms, and hospital in-patient departments	up to 120 days from enrollment

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇵🇱 Chrzanow, Poland